Insight Molecular Diagnostics Inc. (IMDX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Insight Molecular Diagnostics Inc. stock (IMDX) is currently trading at $4.00. Insight Molecular Diagnostics Inc. PS ratio (Price-to-Sales) is 27.76. Analyst consensus price target for IMDX is $8.33. WallStSmart rates IMDX as Sell.
- IMDX PE ratio analysis and historical PE chart
- IMDX PS ratio (Price-to-Sales) history and trend
- IMDX intrinsic value — DCF, Graham Number, EPV models
- IMDX stock price prediction 2025 2026 2027 2028 2029 2030
- IMDX fair value vs current price
- IMDX insider transactions and insider buying
- Is IMDX undervalued or overvalued?
- Insight Molecular Diagnostics Inc. financial analysis — revenue, earnings, cash flow
- IMDX Piotroski F-Score and Altman Z-Score
- IMDX analyst price target and Smart Rating
Insight Molecular Diagnostics Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Insight Molecular Diagnostics Inc. (IMDX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Insight Molecular Diagnostics Inc. (IMDX) Key Strengths (2)
Revenue surging 126.10% year-over-year
52.29% held by institutions, strong professional interest
Supporting Valuation Data
Insight Molecular Diagnostics Inc. (IMDX) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 27.8x annual revenue
Very expensive at 196.3x book value
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Insight Molecular Diagnostics Inc. (IMDX) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 126.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (27.76), Price/Book (196.27) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -23603.00%, Operating Margin at -2950.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -23603.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 126.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IMDX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IMDX's Price-to-Sales ratio of 27.76x trades 49% below its historical average of 54.2x (26th percentile). The current valuation is 80% below its historical high of 136.65x set in Jun 2021, and 564% above its historical low of 4.18x in Dec 2022. Over the past 12 months, the PS ratio has compressed from ~48.8x as trailing revenue scaled faster than the stock price.
Compare IMDX with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Insight Molecular Diagnostics Inc. (IMDX) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Insight Molecular Diagnostics Inc. is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 4M with 126% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 126% YoY, reaching 4M. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
Spending 88% of revenue (4M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Insight Molecular Diagnostics Inc. maintain 126%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Insight Molecular Diagnostics Inc..
Bottom Line
Insight Molecular Diagnostics Inc. is a high-conviction growth story with revenue accelerating at 126% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Insight Molecular Diagnostics Inc.(IMDX)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.